To validate the clinical correlation between nuclear/T17-phosphorylated GCLM expression and the response of patients with CRC to oxaliplatin-based chemotherapy (FOLFOX or XELOX regimens), we found that nuclear GCLM or T17-phosphorylated GCLM staining were increased in patients who exhibit a poorer benefit from standard chemotherapy (Fig. 7f). This evidence concerns the gene GCLM and colorectal carcinoma.